PK and Safety of Deflazacort in Pediatric DMD

Phase 1, open-label, single-arm trial of deflazacort in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time 0 to Last Measurable Concentration at Day 1 and Area Under the Plasma Concentration-Time Curve Over the Final Dosing Interval at Day 8. Started Dec 2014; status: completed.